OUR PURPOSE IS SIMPLE:
Patients fighting chronic diseases are often denied access to life-saving treatments.
ICERWatch gives patients a voice to fight back.
What Is ICER?
It's Important for Patients to Know
An organization most patients never heard of is now hard at work determining whether recently approved drugs for serious and often life-threatening diseases should be covered by private health plans and made available to patients. Called the Institute for Clinical and Economic Review (ICER), this Boston-based institute describes itself as “a trustworthy, independent source to help assess how valuable a new drug really is.” Yet, ICER has come under increasing criticism due to the methods it uses to decide the “value” of new medicines, and its ultimate purpose of limiting the use of drugs patients and clinicians need.
The midterms are over and it’s time to get back to discussing issues that impact Americans on a daily basis. Things like health care and,
If you’re suffering from a rare, debilitating disease like MS, or cystic fibrosis, or some forms of cancer, and you need a boutique biologic to
Draft Evidence Report “Biologic Therapies for Treatment of Asthma Associated with Type 2 Inflammation: Effectiveness, Value, and Value-Based Price Benchmarks”
We appreciate the opportunity to provide our comments on the September 24th draft report, “Biologic Therapies for Treatment of Asthma Associated with Type 2 Inflammation:
There’s a little-known group out there that just made several disappointing recommendations for all those living with prostate cancer. Sadly, it could mean the difference
Comment on ICER’s September 7th draft evidence report about pharmacological treatments for Opioid Use Disorder (OUD).
Patients Rising Now welcomes the opportunity to comment on ICER’s September 7th draft evidence report about pharmacological treatments for Opioid Use Disorder (OUD). As you